29C1 Stock Chart & Stats
€1.93
€0.08(3.85%)
At close: 4:00 PM EDT
€1.93
€0.08(3.85%)
Day’s Range― - ―
52-Week Range€1.89 - €2.46
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€136.56M
Enterprise Value€291.62M
Total Cash (Recent Filing)€10.05M
Total Debt (Recent Filing)€76.33M
Price to Earnings (P/E)7.9
Beta0.20
Next Earnings
Nov 04, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.42
Shares Outstanding63,514,038
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)2.19
Price to Sales (P/S)0.65
P/FCF Ratio10.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.07
Revenue Forecast (FY)€242.22M
Bulls Say, Bears Say
Bulls Say
Profitable Growth And Cash GenerationThe return to profitability alongside strong revenue growth indicates a materially improved earnings base. Positive free cash flow and high cash conversion provide internal funding for operations, debt service, and selective growth, supporting resilience over the next several quarters.
Large Retirement-bed Contract WinAdding approximately 3,000 beds expands CareRx’s contracted service base and should increase recurring pharmacy and medication-management revenue. Because management expects the contract to be accretive to consolidated margins over time, it can strengthen scale and earnings visibility.
Improved Balance-sheet LeverageLeverage has declined substantially from earlier levels, reducing balance-sheet risk and improving financial flexibility. The current debt burden appears manageable relative to operating earnings, leaving CareRx better positioned to fund bed additions and absorb normal business volatility.
Bears Say
Thin Operating MarginsAlthough CareRx is profitable, its modest operating margins leave limited protection if costs rise or volumes soften. Small changes in reimbursement, service efficiency, or operating expenses can therefore produce disproportionate effects on net income and cash generation.
Ontario Funding HeadwindThe funding change creates a defined multi-period revenue and earnings burden rather than a one-quarter disruption. Recovery depends on ward-bed redevelopment and is not expected until late 2027, leaving near-term results exposed to weaker volume economics and delayed recapture.
Lower Liquidity And Higher Net DebtThe decline in cash alongside higher net debt reduces near-term financial flexibility, particularly while margins remain thin and funding pressure affects earnings. Continued investment, debt repayment, and shareholder distributions could compete for internally generated cash.
CareRx News
29C1 FAQ
What was CareRx’s price range in the past 12 months?
CareRx lowest stock price was €1.89 and its highest was €2.46 in the past 12 months.
What is CareRx’s market cap?
CareRx’s market cap is €136.56M.
When is CareRx’s upcoming earnings report date?
CareRx’s upcoming earnings report date is Nov 04, 2026 which is in 3 days.
How were CareRx’s earnings last quarter?
CareRx released its earnings results on Jul 29, 2026. The company reported €0.006 earnings per share for the quarter, missing the consensus estimate of €0.015 by -€0.008.
Is CareRx overvalued?
According to Wall Street analysts CareRx’s price is currently Overvalued.
Does CareRx pay dividends?
CareRx does not currently pay dividends.
What is CareRx’s EPS estimate?
CareRx’s EPS estimate is 0.02.
How many shares outstanding does CareRx have?
CareRx has 63,514,038 shares outstanding.
What happened to CareRx’s price movement after its last earnings report?
CareRx reported an EPS of €0.006 in its last earnings report, missing expectations of €0.015. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of CareRx?
Currently, no hedge funds are holding shares in DE:29C1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CareRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.63%
12-Months-Change
Fundamentals
Return on Equity
25.79%
Trailing 12-Months
Asset Growth
11.38%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CareRx
CareRx Corporation, operating with its subsidiaries, specializes in delivering tailored pharmaceutical services to Canada's senior demographic. The company manages a vast network of medication dispensing facilities, which are responsible for providing chronic prescriptions and a variety of other advanced clinical pharmacy solutions. Currently, it caters to approximately 50,000 individuals residing in roughly 900 distinct senior and communal living environments, including extended care residences, retirement communities, supportive living facilities, and group homes. Founded in 2001 and based in Toronto, Canada, the corporation rebranded as CareRx Corporation in June 2020, having formerly been known as Centric Health Corporation.
Technical Analysis
Extendicare
―
Nova Leap Health
―
Sienna Senior Living
―
Medical Facilities
―
WELL Health Technologies Corp
―